Blog
RSS FeedPosted by Michael Wonder on 28 Sep 2020
Sophisticated purchasing of pharmaceuticals: learning from other countries
28 September 2020 - In 2019 and early 2020, drug pricing in the United States was a top concern of ...
Posted by Michael Wonder on 29 Sep 2020
Heron Therapeutics receives European Commission authorisation for Zynrelef (HTX-011) for the treatment of post-operative pain
28 September 2020 - Heron Therapeutics today announced that the European Commission has granted a marketing authorisation for Zynrelef (formerly known ...
Posted by Michael Wonder on 29 Sep 2020
Election campaign 2020: Jacinda Ardern unveils $1 billion health policy
29 September 2020 - Labour is promising to invest millions more in drug-buying agency PHARMAC and emergency dental care if ...
Posted by Michael Wonder on 29 Sep 2020
Shionogi announces FDA approval of Fetroja (cefiderocol) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
29 September 2020 - Shionogi today announces that the U.S. FDA has approved a supplemental new drug application for Fetroja ...
Posted by Michael Wonder on 29 Sep 2020
U.S. FDA approves Pfizer's Xeljanz (tofacitinib) for the treatment of active polyarticular course juvenile idiopathic arthritis
28 September 2020 - Pfizer announced today that the U.S. FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents ...
Posted by Michael Wonder on 28 Sep 2020
Orchard Therapeutics receives EMA PRIME designation for OTL-203 for the treatment of MPS-I
28 September 2020 - Orchard Therapeutics today announced that the EMA has granted Priority Medicines (PRIME) designation to OTL-203, an investigational ...
Posted by Michael Wonder on 28 Sep 2020
Maritime union rejects claims medical supplies and food are being held up in pay dispute
29 September 2020 - There are fears container ships stuck off the Sydney coast could result in major delays to ...
Posted by Michael Wonder on 28 Sep 2020
Worst-rank score methods—a non-parametric approach to informatively missing data
28 September 2020 - A previous JAMA Guide to Statistics and Methods article briefly reviewed non-parametric statistics. ...
Posted by Michael Wonder on 28 Sep 2020
ISPOR introduces new competencies framework for health economics and outcomes research professionals
28 September 2020 - Important step in establishing agreement on the knowledge, skills and attributes required in HEOR. ...
Posted by Michael Wonder on 28 Sep 2020
U.S. FDA approves Haegarda (C1 esterase inhibitor subcutaneous [human]) for prevention of hereditary angioedema attacks in paediatric patients
28 September 2020 - Haegarda is the first and only subcutaneous prophylactic hereditary angioedema treatment approved for children 6 years of ...
Posted by Michael Wonder on 28 Sep 2020
AbbVie receives orphan drug and fast track designations from the U.S. FDA for elezanumab, an investigational monoclonal antibody RGMa inhibitor, for the treatment of spinal cord injury
28 September 2020 - Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury. ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 28 Sep 2020
Khondrion receives rare paediatric disease designation for sonlicromanol from US FDA
28 September 2020 - Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. ...
Posted by Michael Wonder on 28 Sep 2020
Ultomiris (ravulizumab) receives approval in Japan for atypical haemolytic uraemic syndrome in adults and children
25 September 2020 - Ultomiris is the first and only long-acting C5 inhibitor for atypical haemolytic uraemic syndrome, reducing the treatment ...
Posted by Michael Wonder on 28 Sep 2020
Enhertu approved in Japan for the treatment of patients with HER2 positive metastatic gastric cancer
25 September 2020 - Approval of SAKIGAKE designated medicine is based on pivotal phase 2 DESTINY-Gastric01 trial and represents second approval ...